Literature DB >> 8817669

Proteolysis of IGFBPs by cathepsin D in vitro and in cathepsin D-deficient mice.

T Braulke1, M Claussen, P Saftig, M Wendland, K Neifer, B Schmidt, J Zapf, K von Figura, C Peters.   

Abstract

Affinity-purified lysosomal protease cathepsin D cleaved recombinant human IGFBP-1 to -5 in fragments of defined sizes, while IGFBP-6 was not degraded. To assess the role of cathepsin D for proteolytic processing of IGFBP in vivo, serum from cathepsin D-deficient mice and conditioned media from cathepsin D-deficient fibroblasts and organ explants were analyzed. No differences for the pattern and level of IGFBPs were detected. When conditioned media from fibroblasts were incubated at acid pH, proteolysis of IGFBP-1 and -4 was observed only in media derived from cathepsin D-expressing cells. Additional experiments showed that the proteolysis of IGFBP-4 is mediated by cathepsin D and not by a protease activated by cathepsin D. The IGFBP-4 degrading activities in media from organ explants from cathepsin D-deficient mice were found to be sensitive to inhibitors of aspartyl and cysteine proteases. The data indicate that different classes of acid pH-dependent proteases can contribute to the regulation of IGFBP-4 abundance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8817669     DOI: 10.1016/0955-2235(95)00005-4

Source DB:  PubMed          Journal:  Prog Growth Factor Res        ISSN: 0955-2235


  6 in total

1.  Damage control mechanisms in articular cartilage: the role of the insulin-like growth factor I axis.

Authors:  J A Martin; M B Scherb; L A Lembke; J A Buckwalter
Journal:  Iowa Orthop J       Date:  2000

Review 2.  General aspects of insulin-like growth factor binding proteins.

Authors:  K Chan; E M Spencer
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

3.  Haematopoietic development and immunological function in the absence of cathepsin D.

Authors:  Calogero Tulone; Yasuo Uchiyama; Marco Novelli; Nicholas Grosvenor; Paul Saftig; Benjamin M Chain
Journal:  BMC Immunol       Date:  2007-09-26       Impact factor: 3.615

Review 4.  The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.

Authors:  Liesbeth Bieghs; Hans E Johnsen; Ken Maes; Eline Menu; Els Van Valckenborgh; Michael T Overgaard; Mette Nyegaard; Cheryl A Conover; Karin Vanderkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2016-07-26

Review 5.  Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer.

Authors:  Ayse Ceren Mutgan; H Erdinc Besikcioglu; Shenghan Wang; Helmut Friess; Güralp O Ceyhan; Ihsan Ekin Demir
Journal:  Mol Cancer       Date:  2018-02-23       Impact factor: 27.401

Review 6.  Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer.

Authors:  Divya Thomas; Prakash Radhakrishnan
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.